![](/img/cover-not-exists.png)
A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study
Yoshida, T., Kinoshita, H., Taniguchi, H., Yanishi, M., Sugi, M., Matsuda, T.Language:
english
Journal:
Osteoporosis International
DOI:
10.1007/s00198-019-05271-5
Date:
January, 2020
File:
PDF, 730 KB
english, 2020